Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2-3/2014

Open Access 01-09-2014 | NON-THEMATIC REVIEW

The developing story of Sprouty and cancer

Authors: Samar Masoumi-Moghaddam, Afshin Amini, David Lawson Morris

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Login to get access

Abstract

Sprouty proteins are evolutionarily conserved modulators of MAPK/ERK pathway. Through interacting with an increasing number of effectors, mediators, and regulators with ultimate influence on multiple targets within or beyond ERK, Sprouty orchestrates a complex, multilayered regulatory system and mediates a crosstalk among different signaling pathways for a coordinated cellular response. As such, Sprouty has been implicated in various developmental and physiological processes. Evidence shows that ERK is aberrantly activated in malignant conditions. Accordingly, Sprouty deregulation has been reported in different cancer types and shown to impact cancer development, progression, and metastasis. In this article, we have tried to provide an overview of the current knowledge about the Sprouty physiology and its regulatory functions in health, as well as an updated review of the Sprouty status in cancer. Putative implications of Sprouty in cancer biology, their clinical relevance, and their proposed applications are also revisited. As a developing story, however, role of Sprouty in cancer remains to be further elucidated.
Literature
1.
Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., & Krasnow, M. A. (1998). Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell, 92(2), 253–263.PubMed
2.
Kramer, S., Okabe, M., Hacohen, N., Krasnow, M. A., & Hiromi, Y. (1999). Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Development, 126(11), 2515–2525.PubMed
3.
de Maximy, A. A., Nakatake, Y., Moncada, S., Itoh, N., Thiery, J. P., & Bellusci, S. (1999). Cloning and expression pattern of a mouse homologue of drosophila sprouty in the mouse embryo. [Research Support, Non-U.S. Gov't]. Mechanisms of Development, 81(1–2), 213–216.PubMed
4.
Leeksma, O. C., Van Achterberg, T. A., Tsumura, Y., Toshima, J., Eldering, E., Kroes, W. G., et al. (2002). Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. European Journal of Biochemistry, 269(10), 2546–2556.PubMed
5.
Gross, I., Bassit, B., Benezra, M., & Licht, J. D. (2001). Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. Journal of Biological Chemistry, 276(49), 46460–46468. doi:10.​1074/​jbc.​M108234200.PubMed
6.
Impagnatiello, M. A., Weitzer, S., Gannon, G., Compagni, A., Cotten, M., & Christofori, G. (2001). Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. Journal of Cell Biology, 152(5), 1087–1098.PubMedCentralPubMed
7.
Wong, E. S., Fong, C. W., Lim, J., Yusoff, P., Low, B. C., Langdon, W. Y., et al. (2002). Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO Journal, 21(18), 4796–4808.PubMedCentralPubMed
8.
Gross, I., Armant, O., Benosman, S., de Aguilar, J. L., Freund, J. N., Kedinger, M., et al. (2007). Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 14(10), 1802–1812. doi:10.​1038/​sj.​cdd.​4402188.PubMed
9.
10.
Minowada, G., Jarvis, L. A., Chi, C. L., Neubuser, A., Sun, X., Hacohen, N., et al. (1999). Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Development, 126(20), 4465–4475.PubMed
11.
Ding, W., Bellusci, S., Shi, W., & Warburton, D. (2004). Genomic structure and promoter characterization of the human Sprouty4 gene, a novel regulator of lung morphogenesis. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. American Journal of Physiology - Lung Cellular and Molecular Physiology, 287(1), L52–L59. doi:10.​1152/​ajplung.​00430.​2003.PubMed
12.
Tefft, J. D., Lee, M., Smith, S., Leinwand, M., Zhao, J., Bringas, P., Jr., et al. (1999). Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. [Research Support, U.S. Gov't, P.H.S.]. Current Biology, 9(4), 219–222.PubMed
13.
Katoh, Y., & Katoh, M. (2006). FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. International Journal of Molecular Medicine, 17(3), 529–532.PubMed
14.
15.
16.
17.
Furthauer, M., Reifers, F., Brand, M., Thisse, B., & Thisse, C. (2001). Sprouty4 acts in vivo as a feedback-induced antagonist of FGF signaling in zebrafish. [Research Support, Non-U.S. Gov't]. Development, 128(12), 2175–2186.PubMed
18.
Zhang, S., Lin, Y., Itaranta, P., Yagi, A., & Vainio, S. (2001). Expression of Sprouty genes 1, 2 and 4 during mouse organogenesis. Mechanisms of Development, 109(2), 367–370.PubMed
19.
Gross, I., Morrison, D. J., Hyink, D. P., Georgas, K., English, M. A., Mericskay, M., et al. (2003). The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. Journal of Biological Chemistry, 278(42), 41420–41430. doi:10.​1074/​jbc.​M306425200.PubMed
20.
Chi, L., Zhang, S., Lin, Y., Prunskaite-Hyyrylainen, R., Vuolteenaho, R., Itaranta, P., et al. (2004). Sprouty proteins regulate ureteric branching by coordinating reciprocal epithelial Wnt11, mesenchymal Gdnf and stromal Fgf7 signalling during kidney development. Development, 131(14), 3345–3356. doi:10.​1242/​dev.​01200.PubMed
21.
Lo, T. L., Yusoff, P., Fong, C. W., Guo, K., McCaw, B. J., Phillips, W. A., et al. (2004). The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Research, 64(17), 6127–6136. doi:10.​1158/​0008-5472.​CAN-04-1207.PubMed
22.
Anteby, E. Y., Natanson-Yaron, S., Greenfield, C., Goldman-Wohl, D., Haimov-Kochman, R., Holzer, H., et al. (2005). Human placental Hofbauer cells express sprouty proteins: a possible modulating mechanism of villous branching. Placenta, 26(6), 476–483. doi:10.​1016/​j.​placenta.​2004.​08.​008.PubMed
23.
Haimov-Kochman, R., Ravhon, A., Prus, D., Greenfield, C., Finci-Yeheskel, Z., Goldman-Wohl, D. S., et al. (2005). Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Molecular Human Reproduction, 11(8), 537–542. doi:10.​1093/​molehr/​gah203.PubMed
24.
Lin, W., Jing, N., Basson, M. A., Dierich, A., Licht, J., & Ang, S. L. (2005). Synergistic activity of Sef and Sprouty proteins in regulating the expression of Gbx2 in the mid-hindbrain region. Genesis, 41(3), 110–115. doi:10.​1002/​gene.​20103.PubMed
25.
Shim, K., Minowada, G., Coling, D. E., & Martin, G. R. (2005). Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Developmental Cell, 8(4), 553–564. doi:10.​1016/​j.​devcel.​2005.​02.​009.PubMed
26.
Basson, M. A., Watson-Johnson, J., Shakya, R., Akbulut, S., Hyink, D., Costantini, F. D., et al. (2006). Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Developmental Biology, 299(2), 466–477. doi:10.​1016/​j.​ydbio.​2006.​08.​051.PubMed
27.
Boros, J., Newitt, P., Wang, Q., McAvoy, J. W., & Lovicu, F. J. (2006). Sef and Sprouty expression in the developing ocular lens: Implications for regulating lens cell proliferation and differentiation. Seminars in Cell and Developmental Biology, 17(6), 741–752. doi:10.​1016/​j.​semcdb.​2006.​10.​007.PubMedCentralPubMed
28.
Chi, L., Itaranta, P., Zhang, S., & Vainio, S. (2006). Sprouty2 is involved in male sex organogenesis by controlling fibroblast growth factor 9-induced mesonephric cell migration to the developing testis. Endocrinology, 147(8), 3777–3788. doi:10.​1210/​en.​2006-0299.PubMed
29.
Natanson-Yaron, S., Anteby, E. Y., Greenfield, C., Goldman-Wohl, D., Hamani, Y., Hochner-Celnikier, D., et al. (2007). FGF 10 and Sprouty 2 modulate trophoblast invasion and branching morphogenesis. Molecular Human Reproduction, 13(7), 511–519. doi:10.​1093/​molehr/​gam034.PubMed
30.
Price, K. L., Long, D. A., Jina, N., Liapis, H., Hubank, M., Woolf, A. S., et al. (2007). Microarray interrogation of human metanephric mesenchymal cells highlights potentially important molecules in vivo. Physiological Genomics, 28(2), 193–202. doi:10.​1152/​physiolgenomics.​00147.​2006.PubMed
31.
Shaw, A. T., Meissner, A., Dowdle, J. A., Crowley, D., Magendantz, M., Ouyang, C., et al. (2007). Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes and Development, 21(6), 694–707. doi:10.​1101/​gad.​1526207.PubMedCentralPubMed
32.
Laziz, I., Armand, A. S., Pariset, C., Lecolle, S., Della Gaspera, B., Charbonnier, F., et al. (2007). Sprouty gene expression is regulated by nerve and FGF6 during regeneration of mouse muscles. Growth Factors, 25(3), 151–159. doi:10.​1080/​0897719070172316​6.PubMed
33.
Hamel, M., Dufort, I., Robert, C., Gravel, C., Leveille, M. C., Leader, A., et al. (2008). Identification of differentially expressed markers in human follicular cells associated with competent oocytes. Human Reproduction, 23(5), 1118–1127. doi:10.​1093/​humrep/​den048.PubMed
34.
Klein, O. D., Lyons, D. B., Balooch, G., Marshall, G. W., Basson, M. A., Peterka, M., et al. (2008). An FGF signaling loop sustains the generation of differentiated progeny from stem cells in mouse incisors. Development, 135(2), 377–385. doi:10.​1242/​dev.​015081.PubMedCentralPubMed
35.
Jaggi, F., Cabrita, M. A., Perl, A. K., & Christofori, G. (2008). Modulation of endocrine pancreas development but not beta-cell carcinogenesis by Sprouty4. Molecular Cancer Research, 6(3), 468–482. doi:10.​1158/​1541-7786.​mcr-07-0255.PubMed
36.
Wang, Y., Janicki, P., Koster, I., Berger, C. D., Wenzl, C., Grosshans, J., et al. (2008). Xenopus paraxial protocadherin regulates morphogenesis by antagonizing Sprouty. Genes and Development, 22(7), 878–883. doi:10.​1101/​gad.​452908.PubMedCentralPubMed
37.
38.
39.
Sieglitz, F., Matzat, T., Yuva-Adyemir, Y., Neuert, H., Altenhein, B., & Klambt, C. (2013). Antagonistic feedback loops involving rau and sprouty in the Drosophila eye control neuronal and glial differentiation. Science Signaling, 6(300), ra96. doi:10.​1126/​scisignal.​2004651.PubMed
40.
41.
42.
43.
Ching, S. T., Cunha, G. R., Baskin, L. S., Basson, M. A., & Klein, O. D. (2014). Coordinated activity of Spry1 and Spry2 is required for normal development of the external genitalia. Developmental Biology, 386(1), 1–11. doi:10.​1016/​j.​ydbio.​2013.​12.​014.PubMed
44.
Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A., & Swain, J. L. (2001). Inhibition of angiogenesis by a mouse sprouty protein. Journal of Biological Chemistry, 276(6), 4128–4133. doi:10.​1074/​jbc.​M006922200.PubMed
45.
Huebert, R. C., Li, Q., Adhikari, N., Charles, N. J., Han, X., Ezzat, M. K., et al. (2004). Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiological Genomics, 18(3), 284–289. doi:10.​1152/​physiolgenomics.​00098.​2004.PubMed
46.
Poppleton, H. M., Edwin, F., Jaggar, L., Ray, R., Johnson, L. R., & Patel, T. B. (2004). Sprouty regulates cell migration by inhibiting the activation of Rac1 GTPase. Biochemical and Biophysical Research Communications, 323(1), 98–103. doi:10.​1016/​j.​bbrc.​2004.​08.​070.PubMed
47.
Zhang, C., Chaturvedi, D., Jaggar, L., Magnuson, D., Lee, J. M., & Patel, T. B. (2005). Regulation of vascular smooth muscle cell proliferation and migration by human sprouty 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(3), 533–538. doi:10.​1161/​01.​ATV.​0000155461.​50450.​5a.PubMed
48.
de Alvaro, C., Martinez, N., Rojas, J. M., & Lorenzo, M. (2005). Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Molecular Biology of the Cell, 16(9), 4454–4461. doi:10.​1091/​mbc.​E05-05-0419.PubMedCentralPubMed
49.
Tsumura, Y., Toshima, J., Leeksma, O. C., Ohashi, K., & Mizuno, K. (2005). Sprouty-4 negatively regulates cell spreading by inhibiting the kinase activity of testicular protein kinase. Biochemical Journal, 387(Pt 3), 627–637. doi:10.​1042/​BJ20041181.PubMedCentralPubMed
50.
Fong, C. W., Chua, M. S., McKie, A. B., Ling, S. H., Mason, V., Li, R., et al. (2006). Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Research, 66(4), 2048–2058. doi:10.​1158/​0008-5472.​CAN-05-1072.PubMed
51.
Wang, J., Thompson, B., Ren, C., Ittmann, M., & Kwabi-Addo, B. (2006). Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate, 66(6), 613–624. doi:10.​1002/​pros.​20353.PubMed
52.
Sutterluty, H., Mayer, C. E., Setinek, U., Attems, J., Ovtcharov, S., Mikula, M., et al. (2007). Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Molecular Cancer Research, 5(5), 509–520. doi:10.​1158/​1541-7786.​MCR-06-0273.PubMed
53.
Ding, W., Shi, W., Bellusci, S., Groffen, J., Heisterkamp, N., Minoo, P., et al. (2007). Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells. Journal of Cellular Physiology, 212(3), 796–806. doi:10.​1002/​jcp.​21078.PubMed
54.
55.
Lito, P., Mets, B. D., Appledorn, D. M., Maher, V. M., & McCormick, J. J. (2009). Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. Journal of Biological Chemistry, 284(2), 848–854. doi:10.​1074/​jbc.​M808045200.PubMedCentralPubMed
56.
Tennis, M. A., Van Scoyk, M. M., Freeman, S. V., Vandervest, K. M., Nemenoff, R. A., & Winn, R. A. (2010). Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Molecular Cancer Research, 8(6), 833–843. doi:10.​1158/​1541-7786.​mcr-09-0400.PubMedCentralPubMed
57.
Jung, J. E., Moon, S. H., Kim, D. K., Choi, C., Song, J., & Park, K. S. (2012). Sprouty1 regulates neural and endothelial differentiation of mouse embryonic stem cells. Stem Cells and Development, 21(4), 554–561. doi:10.​1089/​scd.​2011.​0110.PubMed
58.
Felfly, H., & Klein, O. D. (2013). Sprouty genes regulate proliferation and survival of human embryonic stem cells. Science Reports, 3, 2277. doi:10.​1038/​srep02277.
59.
Mekkawy, A. H., & Morris, D. L. (2013). Human Sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion. ISRN Biochem, 2013, 7. doi:10.​1155/​2013/​598251.
60.
Sasaki, A., Taketomi, T., Wakioka, T., Kato, R., & Yoshimura, A. (2001). Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor—but not epidermal growth factor-induced ERK activation. Journal of Biological Chemistry, 276(39), 36804–36808. doi:10.​1074/​jbc.​C100386200.PubMed
61.
Yigzaw, Y., Cartin, L., Pierre, S., Scholich, K., & Patel, T. B. (2001). The C terminus of sprouty is important for modulation of cellular migration and proliferation. Journal of Biological Chemistry, 276(25), 22742–22747. doi:10.​1074/​jbc.​M100123200.PubMed
62.
Yigzaw, Y., Poppleton, H. M., Sreejayan, N., Hassid, A., & Patel, T. B. (2003). Protein-tyrosine phosphatase-1B (PTP1B) mediates the anti-migratory actions of Sprouty. Journal of Biological Chemistry, 278(1), 284–288. doi:10.​1074/​jbc.​M210359200.PubMed
63.
Lee, C. C., Putnam, A. J., Miranti, C. K., Gustafson, M., Wang, L. M., Vande Woude, G. F., et al. (2004). Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene, 23(30), 5193–5202. doi:10.​1038/​sj.​onc.​1207646.PubMed
64.
Edwin, F., Singh, R., Endersby, R., Baker, S. J., & Patel, T. B. (2006). The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. Journal of Biological Chemistry, 281(8), 4816–4822. doi:10.​1074/​jbc.​M508300200.PubMed
65.
66.
Lee, S. A., Ho, C., Roy, R., Kosinski, C., Patil, M. A., Tward, A. D., et al. (2008). Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology, 47(4), 1200–1210. doi:10.​1002/​hep.​22169.PubMed
67.
Frank, M. J., Dawson, D. W., Bensinger, S. J., Hong, J. S., Knosp, W. M., Xu, L., et al. (2009). Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood, 113(11), 2478–2487. doi:10.​1182/​blood-2008-05-156943.PubMedCentralPubMed
68.
Holgren, C., Dougherty, U., Edwin, F., Cerasi, D., Taylor, I., Fichera, A., et al. (2010). Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Oncogene, 29(38), 5241–5253. doi:10.​1038/​onc.​2010.​264.PubMedCentralPubMed
69.
Barbachano, A., Ordonez-Moran, P., Garcia, J. M., Sanchez, A., Pereira, F., Larriba, M. J., et al. (2010). SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene, 29(34), 4800–4813. doi:10.​1038/​onc.​2010.​225.PubMed
70.
Schaaf, G., Hamdi, M., Zwijnenburg, D., Lakeman, A., Geerts, D., Versteeg, R., et al. (2010). Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Research, 70(2), 762–771. doi:10.​1158/​0008-5472.​can-09-2532.PubMed
71.
72.
73.
74.
Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80(2), 179–185.PubMed
75.
Kim, H. J., & Bar-Sagi, D. (2004). Modulation of signalling by Sprouty: a developing story. Nature Reviews Molecular Cell Biology, 5(6), 441–450. doi:10.​1038/​nrm1400.PubMed
76.
Sasaki, A., Taketomi, T., Kato, R., Saeki, K., Nonami, A., Sasaki, M., et al. (2003). Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nature Cell Biology, 5(5), 427–432. doi:10.​1038/​ncb978.PubMed
77.
Kao, S., Jaiswal, R. K., Kolch, W., & Landreth, G. E. (2001). Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. Journal of Biological Chemistry, 276(21), 18169–18177. doi:10.​1074/​jbc.​M008870200.PubMed
78.
Ozaki, K., Kadomoto, R., Asato, K., Tanimura, S., Itoh, N., & Kohno, M. (2001). ERK pathway positively regulates the expression of Sprouty genes. [Research Support, Non-U.S. Gov't]. Biochemical and Biophysical Research Communications, 285(5), 1084–1088. doi:10.​1006/​bbrc.​2001.​5295.PubMed
79.
Kral, R. M., Mayer, C. E., Vanas, V., Gsur, A., & Sutterluty-Fall, H. (2013). In non-small cell lung cancer mitogenic signaling leaves Sprouty1 protein levels unaffected. Cell Biochemistry and Function. doi:10.​1002/​cbf.​2976.PubMed
80.
Hausott, B., Vallant, N., Auer, M., Yang, L., Dai, F., Brand-Saberi, B., et al. (2009). Sprouty2 down-regulation promotes axon growth by adult sensory neurons. Molecular and Cellular Neuroscience, 42(4), 328–340. doi:10.​1016/​j.​mcn.​2009.​08.​005.PubMed
81.
82.
Choi, H., Cho, S. Y., Schwartz, R. H., & Choi, K. (2006). Dual effects of Sprouty1 on TCR signaling depending on the differentiation state of the T cell. Journal of Immunology, 176(10), 6034–6045.
83.
Jiang, Z., & Price, C. A. (2012). Differential actions of fibroblast growth factors on intracellular pathways and target gene expression in bovine ovarian granulosa cells. Reproduction, 144(5), 625–632. doi:10.​1530/​rep-12-0199.PubMed
84.
Jiang, Z., Guerrero-Netro, H. M., Juengel, J. L., & Price, C. A. (2013). Divergence of intracellular signaling pathways and early response genes of two closely related fibroblast growth factors, FGF8 and FGF18, in bovine ovarian granulosa cells. Molecular and Cellular Endocrinology, 375(1–2), 97–105. doi:10.​1016/​j.​mce.​2013.​05.​017.PubMed
85.
Ding, W., Bellusci, S., Shi, W., & Warburton, D. (2003). Functional analysis of the human Sprouty2 gene promoter. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Gene, 322, 175–185.PubMed
86.
Sabatel, C., Cornet, A. M., Tabruyn, S. P., Malvaux, L., Castermans, K., Martial, J. A., et al. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9, 231. doi:10.​1186/​1476-4598-9-231.PubMedCentralPubMed
87.
Hall, A. B., Jura, N., DaSilva, J., Jang, Y. J., Gong, D., & Bar-Sagi, D. (2003). hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Current Biology, 13(4), 308–314.PubMed
88.
Rubin, C., Litvak, V., Medvedovsky, H., Zwang, Y., Lev, S., & Yarden, Y. (2003). Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Current Biology, 13(4), 297–307.PubMed
89.
Mason, J. M., Morrison, D. J., Bassit, B., Dimri, M., Band, H., Licht, J. D., et al. (2004). Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Molecular Biology of the Cell, 15(5), 2176–2188. doi:10.​1091/​mbc.​E03-07-0503.PubMedCentralPubMed
90.
Mason, J. M., Morrison, D. J., Basson, M. A., & Licht, J. D. (2006). Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Trends in Cell Biology, 16(1), 45–54. doi:10.​1016/​j.​tcb.​2005.​11.​004.PubMed
91.
Mayer, C. E., Haigl, B., Jantscher, F., Siegwart, G., Grusch, M., Berger, W., et al. (2010). Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cellular and Molecular Life Sciences, 67(19), 3299–3311. doi:10.​1007/​s00018-010-0379-6.PubMed
92.
93.
94.
Nadeau, R. J., Toher, J. L., Yang, X., Kovalenko, D., & Friesel, R. (2007). Regulation of Sprouty2 stability by mammalian Seven-in-Absentia homolog 2. Journal of Cellular Biochemistry, 100(1), 151–160. doi:10.​1002/​jcb.​21040.PubMed
95.
Qi, J., Nakayama, K., Gaitonde, S., Goydos, J. S., Krajewski, S., Eroshkin, A., et al. (2008). The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proceedings of the National Academy of Sciences of the United States of America, 105(43), 16713–16718. doi:10.​1073/​pnas.​0804063105.PubMedCentralPubMed
96.
Haigl, B., Mayer, C. E., Siegwart, G., & Sutterluty, H. (2010). Sprouty4 levels are increased under hypoxic conditions by enhanced mRNA stability and transcription. Biological Chemistry, 391(7), 813–821. doi:10.​1515/​bc.​2010.​082.PubMed
97.
Anderson, K., Nordquist, K. A., Gao, X., Hicks, K. C., Zhai, B., Gygi, S. P., et al. (2011). Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. [Research Support, N.I.H., Extramural]. Journal of Biological Chemistry, 286(49), 42027–42036. doi:10.​1074/​jbc.​M111.​303222.PubMedCentralPubMed
98.
Lim, J., Wong, E. S., Ong, S. H., Yusoff, P., Low, B. C., & Guy, G. R. (2000). Sprouty proteins are targeted to membrane ruffles upon growth factor receptor tyrosine kinase activation. Identification of a novel translocation domain. Journal of Biological Chemistry, 275(42), 32837–32845. doi:10.​1074/​jbc.​M002156200.PubMed
99.
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002). Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. [Research Support, Non-U.S. Gov't]. Nature Cell Biology, 4(11), 850–858. doi:10.​1038/​ncb867.PubMed
100.
Lim, J., Yusoff, P., Wong, E. S., Chandramouli, S., Lao, D. H., Fong, C. W., et al. (2002). The cysteine-rich sprouty translocation domain targets mitogen-activated protein kinase inhibitory proteins to phosphatidylinositol 4,5-bisphosphate in plasma membranes. Molecular and Cellular Biology, 22(22), 7953–7966.PubMedCentralPubMed
101.
Cabrita, M. A., Jaggi, F., Widjaja, S. P., & Christofori, G. (2006). A functional interaction between sprouty proteins and caveolin-1. Journal of Biological Chemistry, 281(39), 29201–29212. doi:10.​1074/​jbc.​M603921200.PubMed
102.
Hwangpo, T. A., Jordan, J. D., Premsrirut, P. K., Jayamaran, G., Licht, J. D., Iyengar, R., et al. (2012). G Protein-regulated inducer of neurite outgrowth (GRIN) modulates Sprouty protein repression of mitogen-activated protein kinase (MAPK) activation by growth factor stimulation. Journal of Biological Chemistry, 287(17), 13674–13685. doi:10.​1074/​jbc.​M111.​320705.PubMedCentralPubMed
103.
Fong, C. W., Leong, H. F., Wong, E. S., Lim, J., Yusoff, P., & Guy, G. R. (2003). Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. [Research Support, Non-U.S. Gov't]. Journal of Biological Chemistry, 278(35), 33456–33464. doi:10.​1074/​jbc.​M301317200.PubMed
104.
Rubin, C., Zwang, Y., Vaisman, N., Ron, D., & Yarden, Y. (2005). Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. Journal of Biological Chemistry, 280(10), 9735–9744. doi:10.​1074/​jbc.​M408308200.PubMed
105.
Lao, D. H., Yusoff, P., Chandramouli, S., Philp, R. J., Fong, C. W., Jackson, R. A., et al. (2007). Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation. Journal of Biological Chemistry, 282(12), 9117–9126. doi:10.​1074/​jbc.​M607563200.PubMed
106.
Lao, D. H., Chandramouli, S., Yusoff, P., Fong, C. W., Saw, T. Y., Tai, L. P., et al. (2006). A Src homology 3-binding sequence on the C terminus of Sprouty2 is necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor stimulation. Journal of Biological Chemistry, 281(40), 29993–30000. doi:10.​1074/​jbc.​M604044200.PubMed
107.
Chandramouli, S., Yu, C. Y., Yusoff, P., Lao, D. H., Leong, H. F., Mizuno, K., et al. (2008). Tesk1 interacts with Spry2 to abrogate its inhibition of ERK phosphorylation downstream of receptor tyrosine kinase signaling. Journal of Biological Chemistry, 283(3), 1679–1691. doi:10.​1074/​jbc.​M705457200.PubMed
108.
Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., & Nishida, E. (2004). Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. Journal of Biological Chemistry, 279(22), 22992–22995. doi:10.​1074/​jbc.​M312498200.PubMed
109.
Jarvis, L. A., Toering, S. J., Simon, M. A., Krasnow, M. A., & Smith-Bolton, R. K. (2006). Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases. Development, 133(6), 1133–1142. doi:10.​1242/​dev.​02255.PubMed
110.
Patel, R., Gao, M., Ahmad, I., Fleming, J., Singh, L. B., Rai, T. S., et al. (2013). Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 123(3), 1157–1175. doi:10.​1172/​jci63672.PubMedCentralPubMed
111.
Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G., & Bastiaens, P. I. (2002). Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science, 295(5560), 1708–1711. doi:10.​1126/​science.​1067566.PubMed
112.
Egan, J. E., Hall, A. B., Yatsula, B. A., & Bar-Sagi, D. (2002). The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proceedings of the National Academy of Sciences of the United States of America, 99(9), 6041–6046. doi:10.​1073/​pnas.​052090899.PubMedCentralPubMed
113.
Wong, E. S., Lim, J., Low, B. C., Chen, Q., & Guy, G. R. (2001). Evidence for direct interaction between Sprouty and Cbl. Journal of Biological Chemistry, 276(8), 5866–5875. doi:10.​1074/​jbc.​M006945200.PubMed
114.
115.
Aranda, S., Alvarez, M., Turro, S., Laguna, A., & de la Luna, S. (2008). Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A. Molecular and Cellular Biology, 28(19), 5899–5911. doi:10.​1128/​MCB.​00394-08.PubMedCentralPubMed
116.
Reich, A., Sapir, A., & Shilo, B. (1999). Sprouty is a general inhibitor of receptor tyrosine kinase signaling. [Research Support, Non-U.S. Gov't]. Development, 126(18), 4139–4147.PubMed
117.
Tsavachidou, D., Coleman, M. L., Athanasiadis, G., Li, S. X., Licht, J. D., Olson, M. F., et al. (2004). SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Research, 64(16), 5556–5559.PubMed
118.
Yusoff, P., Lao, D. H., Ong, S. H., Wong, E. S., Lim, J., Lo, T. L., et al. (2002). Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. Journal of Biological Chemistry, 277(5), 3195–3201. doi:10.​1074/​jbc.​M108368200.PubMed
119.
Ayada, T., Taniguchi, K., Okamoto, F., Kato, R., Komune, S., Takaesu, G., et al. (2009). Sprouty4 negatively regulates protein kinase C activation by inhibiting phosphatidylinositol 4,5-biphosphate hydrolysis. Oncogene, 28(8), 1076–1088. doi:10.​1038/​onc.​2008.​464.PubMed
120.
121.
122.
Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P. P., & Dikic, I. (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nature Cell Biology, 5(5), 461–466. doi:10.​1038/​ncb983.PubMed
123.
Mosesson, Y., Shtiegman, K., Katz, M., Zwang, Y., Vereb, G., Szollosi, J., et al. (2003). Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. Journal of Biological Chemistry, 278(24), 21323–21326. doi:10.​1074/​jbc.​C300096200.PubMed
124.
Petrelli, A., Gilestro, G. F., Lanzardo, S., Comoglio, P. M., Migone, N., & Giordano, S. (2002). The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature, 416(6877), 187–190. doi:10.​1038/​416187a.PubMed
125.
Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y., & Dikic, I. (2002). Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature, 416(6877), 183–187. doi:10.​1038/​416183a.PubMed
126.
Kowanetz, K., Szymkiewicz, I., Haglund, K., Kowanetz, M., Husnjak, K., Taylor, J. D., et al. (2003). Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors. Journal of Biological Chemistry, 278(41), 39735–39746. doi:10.​1074/​jbc.​M304541200.PubMed
127.
128.
129.
Ozaki, K., Miyazaki, S., Tanimura, S., & Kohno, M. (2005). Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. Journal of Cell Science, 118(Pt 24), 5861–5871. doi:10.​1242/​jcs.​02711.PubMed
130.
Frolov, A., Chahwan, S., Ochs, M., Arnoletti, J. P., Pan, Z. Z., Favorova, O., et al. (2003). Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Molecular Cancer Therapeutics, 2(8), 699–709.PubMed
131.
Feng, Y. H., Tsao, C. J., Wu, C. L., Chang, J. G., Lu, P. J., Yeh, K. T., et al. (2010). Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Science, 101(9), 2033–2038. doi:10.​1111/​j.​1349-7006.​2010.​01637.​x.PubMed
132.
133.
Sirivatanauksorn, Y., Sirivatanauksorn, V., Srisawat, C., Khongmanee, A., & Tongkham, C. (2012). Differential expression of sprouty genes in hepatocellular carcinoma. Journal of Surgical Oncology, 105(3), 273–276. doi:10.​1002/​jso.​22095.PubMed
134.
Song, K., Gao, Q., Zhou, J., Qiu, S. J., Huang, X. W., Wang, X. Y., et al. (2012). Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. [Research Support, Non-U.S. Gov't]. Hepatobiliary & Pancreatic Diseases International, 11(2), 177–184.
135.
McKie, A. B., Douglas, D. A., Olijslagers, S., Graham, J., Omar, M. M., Heer, R., et al. (2005). Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene, 24(13), 2166–2174. doi:10.​1038/​sj.​onc.​1208371.PubMed
136.
Winn, R. A., Marek, L., Han, S. Y., Rodriguez, K., Rodriguez, N., Hammond, M., et al. (2005). Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Journal of Biological Chemistry, 280(20), 19625–19634. doi:10.​1074/​jbc.​M409392200.PubMed
137.
Feng, Y. H., Wu, C. L., Tsao, C. J., Chang, J. G., Lu, P. J., Yeh, K. T., et al. (2011). Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease. Cancer Biology and Therapy, 11(1), 111–121.PubMed
138.
Dorman, K., Shen, Z., Yang, C., Ezzat, S., & Asa, S. L. (2012). CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia. Molecular Endocrinology, 26(3), 447–457. doi:10.​1210/​me.​2011-1095.PubMed
139.
140.
141.
Lito, P., Mets, B. D., Kleff, S., O'Reilly, S., Maher, V. M., & McCormick, J. J. (2008). Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. Journal of Biological Chemistry, 283(4), 2002–2009. doi:10.​1074/​jbc.​M709046200.PubMed
142.
Kanetsky, P. A., Mitra, N., Vardhanabhuti, S., Li, M., Vaughn, D. J., Letrero, R., et al. (2009). Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nature Genetics, 41(7), 811–815. doi:10.​1038/​ng.​393.PubMedCentralPubMed
143.
Kwabi-Addo, B., Wang, J., Erdem, H., Vaid, A., Castro, P., Ayala, G., et al. (2004). The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Research, 64(14), 4728–4735. doi:10.​1158/​0008-5472.​CAN-03-3759.PubMed
144.
145.
Mekkawy, A. H., De Bock, C. E., Lin, Z., Morris, D. L., Wang, Y., & Pourgholami, M. H. (2010). Novel protein interactors of urokinase-type plasminogen activator receptor. Biochemical and Biophysical Research Communications, 399(4), 738–743. doi:10.​1016/​j.​bbrc.​2010.​08.​010.PubMed
146.
Vanas, V., Muhlbacher, E., Kral, R., & Sutterluty-Fall, H. (2014). Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumour Biology. doi:10.​1007/​s13277-013-1587-0.PubMed
147.
Kwabi-Addo, B., Ren, C., & Ittmann, M. (2009). DNA methylation and aberrant expression of Sprouty1 in human prostate cancer. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Epigenetics, 4(1), 54–61.PubMed
148.
149.
Fritzsche, S., Kenzelmann, M., Hoffmann, M. J., Muller, M., Engers, R., Grone, H. J., et al. (2006). Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocrine-Related Cancer, 13(3), 839–849. doi:10.​1677/​erc.​1.​01190.PubMed
150.
151.
Di Cristofano, A., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nature Genetics, 19(4), 348–355. doi:10.​1038/​1235.PubMed
152.
153.
Harada, N., Miyoshi, H., Murai, N., Oshima, H., Tamai, Y., Oshima, M., et al. (2002). Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Research, 62(7), 1971–1977.PubMed
154.
Harada, N., Oshima, H., Katoh, M., Tamai, Y., Oshima, M., & Taketo, M. M. (2004). Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Research, 64(1), 48–54.PubMed
155.
Lee, S. A., Ladu, S., Evert, M., Dombrowski, F., De Murtas, V., Chen, X., et al. (2010). Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology, 52(2), 506–517. doi:10.​1002/​hep.​23681.PubMedCentralPubMed
156.
157.
Bren-Mattison, Y., Van Putten, V., Chan, D., Winn, R., Geraci, M. W., & Nemenoff, R. A. (2005). Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene, 24(8), 1412–1422. doi:10.​1038/​sj.​onc.​1208333.PubMed
158.
Winn, R. A., Van Scoyk, M., Hammond, M., Rodriguez, K., Crossno, J. T., Jr., Heasley, L. E., et al. (2006). Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry, 281(37), 26943–26950. doi:10.​1074/​jbc.​M604145200.PubMed
159.
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6(1), 1–6.PubMedCentralPubMed
160.
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., et al. (2011). Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. European Journal of Cancer, 47(13), 1946–1954. doi:10.​1016/​j.​ejca.​2011.​03.​029.PubMed
161.
162.
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456(7224), 980–984. doi:10.​1038/​nature07511.PubMed
163.
Huang, Z. P., Chen, J. F., Regan, J. N., Maguire, C. T., Tang, R. H., Dong, X. R., et al. (2010). Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(12), 2575–2586. doi:10.​1161/​atvbaha.​110.​213306.PubMedCentralPubMed
164.
Bloethner, S., Chen, B., Hemminki, K., Muller-Berghaus, J., Ugurel, S., Schadendorf, D., et al. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis, 26(7), 1224–1232. doi:10.​1093/​carcin/​bgi066.PubMed
165.
Quigley, D. A., To, M. D., Kim, I. J., Lin, K. K., Albertson, D. G., Sjolund, J., et al. (2011). Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biology, 12(1), R5. doi:10.​1186/​gb-2011-12-1-r5.PubMedCentralPubMed
166.
Mathieu, V., Pirker, C., Schmidt, W. M., Spiegl-Kreinecker, S., Lotsch, D., Heffeter, P., et al. (2012). Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget, 3(4), 399–413.PubMedCentralPubMed
167.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., et al. (2005). Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Research, 65(20), 9226–9235. doi:10.​1158/​0008-5472.​can-05-1699.PubMed
168.
Nielsen, T. O., West, R. B., Linn, S. C., Alter, O., Knowling, M. A., O'Connell, J. X., et al. (2002). Molecular characterisation of soft tissue tumours: a gene expression study. Lancet, 359(9314), 1301–1307. doi:10.​1016/​s0140-6736(02)08270-3.PubMed
169.
Rathmanner, N., Haigl, B., Vanas, V., Doriguzzi, A., Gsur, A., & Sutterluty-Fall, H. (2013). Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells. FEBS Letters, 587(16), 2597–2605. doi:10.​1016/​j.​febslet.​2013.​06.​040.PubMed
170.
Holtkamp, N., Mautner, V. F., Friedrich, R. E., Harder, A., Hartmann, C., Theallier-Janko, A., et al. (2004). Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathologica, 107(2), 159–168. doi:10.​1007/​s00401-003-0797-8.PubMed
171.
172.
Sanchez, A., Setien, F., Martinez, N., Oliva, J. L., Herranz, M., Fraga, M. F., et al. (2008). Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene, 27(36), 4969–4972. doi:10.​1038/​onc.​2008.​129.PubMed
173.
Macia, A., Vaquero, M., Gou-Fabregas, M., Castelblanco, E., Valdivielso, J. M., Anerillas, C., et al. (2014). Sprouty1 induces a senescence-associated secretory phenotype by regulating NFkappaB activity: implications for tumorigenesis. Cell Death and Differentiation, 21(2), 333–343. doi:10.​1038/​cdd.​2013.​161.PubMed
174.
Polytarchou, C., Iliopoulos, D., Hatziapostolou, M., Kottakis, F., Maroulakou, I., Struhl, K., et al. (2011). Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Research, 71(13), 4720–4731. doi:10.​1158/​0008-5472.​can-11-0365.PubMedCentralPubMed
175.
Moghaddam, S. M., Amini, A., Wei, A. Q., Pourgholami, M. H., & Morris, D. L. (2012). Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. Journal of Oncology, 2012, 373826. doi:10.​1155/​2012/​373826.PubMedCentralPubMed
176.
Takahashi, M., Rhodes, D. R., Furge, K. A., Kanayama, H., Kagawa, S., Haab, B. B., et al. (2001). Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. [Comparative Study Research Support, Non-U.S. Gov't Validation Studies]. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9754–9759. doi:10.​1073/​pnas.​171209998.PubMedCentralPubMed
Metadata
Title
The developing story of Sprouty and cancer
Authors
Samar Masoumi-Moghaddam
Afshin Amini
David Lawson Morris
Publication date
01-09-2014
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9497-1

Other articles of this Issue 2-3/2014

Cancer and Metastasis Reviews 2-3/2014 Go to the issue

OriginalPaper

Src signaling pathways in prostate cancer

NON-THEMATIC REVIEW

Advances in genomic characterization of circulating tumor cells

Acknowledgments

Biography—Elisabeth I. Heath, MD FACP

NON-THEMATIC REVIEW

Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies

CLINICAL

Emerging strategies to overcome resistance to endocrine therapy for breast cancer

OriginalPaper

Recent progress on nutraceutical research in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits